Amgen agreed to buy Otezla for $13.4 billion in cash, in a deal that would pave the way for Bristol-Myers to complete its acquisition of Celgene
Updated Aug. 26, 2019 7:02 am ET
Amgen Inc. said Monday it had agreed to buy the psoriasis treatment Otezla from Celgene Corp. for $13.4 billion in cash in a deal that will pave the way for Bristol-Myers Squibb Co. to complete its acquisition of Celgene. Amgen said the deal is valued at about $11.2 billion, net of the present value of $2.2 billion in anticipated future cash tax benefits.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Why Hasbro's $4 Billion Studio Buy May Trigger More Media MergersThe toymaker's move to snap up Entertainment One is another salvo in an M&A shootout that puts more smaller and mid-sized entertainment companies — such as Lionsgate, AMC Networks and MGM — in play.
Baca lebih lajut »
Greenlanders say Donald Trump should have asked them firstDonald Trump’s offer might make Greenlanders and Danes appreciate one another more, says one islander
Baca lebih lajut »
Scott Disick Bought Sofia Richie the Fanciest 21st B-Day PresentScott Disick bought Sofia Richie the fanciest car for her 21st birthday—check it out here.
Baca lebih lajut »
How Did This Become Everyone’s Favorite Selfie Mirror?Diving into the history of the high-design mirror that's been long-beloved by the fashion world
Baca lebih lajut »
Trump Wanted to Nuke Hurricanes to Stop Them From Hitting U.S. Coast: ReportOne staffer in the briefing gave the evergreen my-boss-is-dumb response to Trump's hurricane proposal: “Sir, we’ll look into that.”
Baca lebih lajut »